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Abstract

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that
affects multiple organ systems within the female body, hallmarked by
infertility, the possibility of androgen excess, and the possibility of
ovulatory dysfunction. Along with a myriad of physiological symptoms,
PCOS is also associated with many psychological issues, including an
increased incidence of depression, anxiety, and lower reported quality of
life among women diagnosed with PCOS. The need for treatment
directed to attenuate any psychological implications of the syndrome has
become increasingly important are of research. While some researchers
have focused on PCOS in a psychosocial perspective, including analysis
on depression, anxiety, and quality of life, more research is needed on
how women with PCOS experience stress. This study examined how 16
women with PCOS physiologically responded to a brief stressor, the
Social Competence Interview (SCI), as compared to a healthy control
population (n=64). Saliva samples were collected at 5 time points (S0S4) before, during, and after the interview to measure cortisol reactivity
to the stressor. Further, the participants were asked to fill out
questionnaires to gather information about their perceived stress, their
psychiatric symptoms, and their physiological health. Results indicated
that women with PCOS reported significantly more somatic complaints
than healthy controls. Women with PCOS also had a higher baseline
cortisol level than healthy controls. Future research should examine
other psychological and physiological factors that could contribute to the
experience of stress in women with PCOS.
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Executive Summary
My capstone project examines how polycystic ovary syndrome (PCOS)
affects the health and well-being of women diagnosed with the syndrome.
Further, my project examines how women with polycystic ovary syndrome
respond to a brief stressor, ultimately aiming to understand how women with
PCOS experience stress.
Polycystic ovary syndrome is a complex, female endocrine disorder with
multiple reproductive and endocrine symptoms. PCOS is the most common
female endocrine disorder worldwide, possibly affecting up to 15% of the
reproductive age population. In the United States alone, 5 million women exhibit
some form of the syndrome. Along with being an incredibly common disorder, it
is also manifests with many problematic symptoms that can negatively impact the
quality of life of women diagnosed. A more detailed description is provided in the
table below.

Table 1. Clinical features of polycystic ovary syndrome
 Infertility (difficulty or not being able to become pregnant) because of not
ovulating.
 Infrequent, absent, and/or irregular menstrual periods
 Androgen excess
 Hirsutism — increased hair growth on the face, chest, stomach, back,
thumbs, or toes
 Cysts on the ovaries
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 Acne, oily skin, or dandruff
 Weight gain or obesity, usually with extra weight around the waist
 Male-pattern baldness or thinning hair
 Patches of skin on the neck, arms, breasts, or thighs that are thick and dark
brown or black
 Skin tags — excess flaps of skin in the armpits or neck area
 Pelvic pain
 Depression and anxiety
 Sleep apnea — when breathing stops for short periods of time while asleep

(Womenshealth.gov, 2013)

PCOS is leading cause of infertility in the United States, accounting for
upwards of 75% of anovulatory infertility. Anovulatory infertility is the inability
to become pregnant because there is an barrier to typical ovulation. As well as
being the leading cause of infertility in the United States, there are other
problematic complications associated with PCOS. About 50% of women
diagnosed with PCOS can expect to develop prediabetes or type II diabetes in
their lifetime, most likely by the age of 40. Moreover, women with PCOS are at a
4 to 7 times greater risk of developing heart disease and having a stroke. With
such an array of physiological problematic symptoms, along with the above
complications, PCOS can have a huge impact on the daily lives of women
diagnosed.
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Along with a myriad of physiological symptoms, women with PCOS
exhibit psychological symptoms. Women with PCOS not only have a higher
prevalence of depressive symptoms, but also are at a greater risk of developing
mood regulation disorders and anxiety. Moreover, women with PCOS are often
found to have a reduced self-reported quality of life than healthy population that
does not have similar issues. Some research has been done on these above
constructs in relation to PCOS; however, more research needs to be conducted on
other psychological implications of being diagnosed with polycystic ovary
syndrome.

While there has been some research done on depression, anxiety, and
quality of life related to PCOS, there has been less research completed on other
psychosocial experiences in women diagnosed with PCOS, such as how women
with PCOS experience stress. It is in this framework that I asked my main
research questions for my project. Firstly, do women with polycystic ovary
syndrome experience stress differently than a healthy control population?
Secondly, how does having PCOS affect the health of women diagnosed? I
expected that women with PCOS would experience stress differently than a
healthy control population, with greater levels of self-reported perceived stress, as
well as having greater physiological reactivity to a brief stressor. Also, I expected
that women with PCOS would report more physical symptoms that they found
concerning in their daily lives than a healthy control population.
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To investigate how women with PCOS experienced stress in their lives, I
conducted a psychology study comparing women diagnosed with polycystic
ovary syndrome with a healthy control population. I recruited women diagnosed
with PCOS from the intro psychology research participation pool, as well as from
the Syracuse University and larger campus communities. Participants were invited
to the Project Heart Lab space, located at the CNY Medical Building near the
Syracuse University campus. Participants were asked to complete a brief series of
questionnaires related to their health and well-being, included a Perceived Stress
Scale, Symptoms Checklist, and the Center for Epidemiological Studies
Depression scale. Also, the participants’ basic body measurements taken (height,
weight, BMI, waist-to-hip ratio), and they were asked to participate in a brief
interview designed to elicit a short term stress response, the Social Competence
Interview (SCI). Throughout the study, saliva samples were taken at five time
points, to later be analyzed for presence of cortisol and amylase. Both cortisol and
amylase are important during the stress response, and from that data, I aimed to
evaluate the reactivity of my participants to brief stressor mentioned above, the
SCI. I analyzed my results using SPSS statistical software. The saliva samples
collected were sent to Brandeis University to be analyzed.
Although we did not find a difference in perceived stress, we did find that
women with PCOS reported more somatic complaints and depressive symptoms
than healthy controls. Given that PCOS is associated with many problematic
physical symptoms, i.e. hirsutism, acne, weight gain, and pelvic pain, it is
expected that women diagnosed with PCOS would have more somatic complaints
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compared to healthy controls. Further, women with PCOS had a significantly
higher levels of baseline cortisol than a healthy, control population.
The findings from this study point to further research on the ties between
the experiences of stress and the relation to physical and psychological health in
women diagnosed with polycystic ovary syndrome. This study supported that
somatic and psychological symptoms associated with PCOS are significantly
different than a healthy population. As a result, more research needs to be
conducted on how these symptoms could affect the daily lives of women affected.
With such a high prevalence among women, affecting over 5 million
women in the United States alone, PCOS is a leading public health concern. As
such, it is imperative that there is increased awareness and research in regards to
the syndrome. Without both of these factors, it is possible that polycystic ovary
syndrome will not receive the attention that it requires for effective treatments to
be developed.
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Advice to Future Honors Students
Rome was not built in a day, and neither will your capstone. This is such a
wonderful learning experience, and can be even more wonderful if you work at it
a little bit every day!
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Introduction
Polycystic Ovary Syndrome
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that
affects multiple organ systems within the female body, hallmarked by infertility,
the possibility of androgen excess, and the possibility of ovulatory dysfunction
(NIH Report, 2012). Ultimately, PCOS is the leading cause of female infertility
(Sheehann, 2004), accounting for upwards of 75% of anovulatory infertility
(Sheehan, 2004). According to the National Institutes of Health report, 5- 15 % of
reproductive-aged women exhibit some phenotype of the syndrome; this accounts
for more than 5 million women in the United States alone (NIH Report, 2012).
Despite the prevalence of this major public health issue (Sanchez, 2014), a long
history of misdiagnosis and non-diagnosis surrounds the syndrome (Colwell et al,
2010). Often, independent symptoms are identified without being attributed to a
chronic health issue (Colwell et al, 2010), making it incredibly difficult for
women to be diagnosed and treated.
In a recent NIH workshop, the syndrome was described as a “poorly
understood condition” for much of the 20th century (NIH Report, 2012). In 1990,
the NIH held a conference to create a standard for diagnoses and research in
regards to the syndrome, dually hoping to obtain a more accurate understanding
of the syndrome and objectives for research (NIH Report, 1990) In a more recent
workshop, the NIH identified three different classifications systems (described in
Table 1) that have been used to diagnose women with PCOS over the past 20
years (NIH Report, 2012). These multiple classifications systems have lead to an
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inevitable miscommunication between practitioner and patient, ultimately serving
as an impediment to diagnoses and treatment (NIH Report, 2012).
Table 2. Differing diagnostic criteria for polycystic ovary syndrome
NIH Criteria (1990)
Chronic anovulation, clinical and/or biochemical signs of
hyperandrogenism (Both criteria needed)
Rotterdam Criteria (2003)
Oligo- and/ or anovulation; clinical and/or biochemical signs of
hyperandrogenism, polycystic ovaries (Two of three criteria needed)
AE-PCOS Society Criteria
Clinical and/or biochemical signs of hyperandrogenism; ovarian
dysfunction (oligo-anovulation and/or polycystic ovarian morphology)
(Two of three criteria needed)

Polycystic ovary syndrome is associated with a wide variety of physiological and
psychological symptoms, some relatively minor, others severe. At its simplest
definition, PCOS is a hormonal imbalance that leads to undesirable symptoms
such as irregular menstruation, changes in appearance, and infertility (NIH
Report, 2012). In actuality, the syndrome is complex and misunderstood, and thus
difficult to treat effectively (Colwell et al, 2010). The complexity of this
syndrome begins with diagnosis: as there is no one set phenotypic expression of
the syndrome, the diagnostic criteria must analyze many aspects of a patient’s
health. To diagnose PCOS, physicians take an extensive medical history of the
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patient, order a series of physiological (physical exam, blood tests, lipid profiling,
and ovarian ultrasound) tests, and take into consideration the symptoms listed
below.
Table 2. Clinical features of polycystic ovary syndrome
 Infertility (difficulty or not being able to become pregnant) because of not
ovulating.
 Infrequent, absent, and/or irregular menstrual periods
 Androgen excess
 Hirsutism — increased hair growth on the face, chest, stomach, back,
thumbs, or toes
 Cysts on the ovaries
 Acne, oily skin, or dandruff
 Weight gain or obesity, usually with extra weight around the waist
 Male-pattern baldness or thinning hair
 Patches of skin on the neck, arms, breasts, or thighs that are thick and dark
brown or black
 Skin tags — excess flaps of skin in the armpits or neck area
 Pelvic pain
 Depression and anxiety
 Sleep apnea — when breathing stops for short periods of time while asleep

(Womenshealth.gov, 2013)

Post diagnoses, the diagnosing practitioner will work on a treatment plan
for the patient. These treatments generally fall into two categories of intervention,
one of which being medication. The goal of treatment with medications is to
attenuate the effects of hormonal abnormalities (excess androgens and estrogens)
in women with the syndrome. Synthetic hormone treatment, commonly in the
form of birth control pills, is provided to dually regulate menstrual cycles and
reduce excessive androgens. Also, for concerns surrounding fertility issues,
women with PCOS are often provided hormonal treatments that target
anovulation. One such example is clomiphene, which has been found to have
some efficacy in treating infertility issues in women with PCOS (Palomba et al,
2009).
Further, a practitioner may provide metformin (Glucophage, Glucophage
Extended Release (XR), to lower insulin levels, increase insulin sensitivity, and
potentially induce ovulation (Mayo Clinic, 2014). Metformin has been found to
help those diagnosed manage the overall disorder through increasing insulin
sensitivity (Nestler, 2002). In summation, these treatments focus on the
biochemical abnormalities that are present in women diagnosed with polycystic
ovary syndrome.
Along with medication intervention, another treatment focus is lifestyle
intervention. Women diagnosed with PCOS are encouraged to eat a healthy diet,
exercise, and if at all possible, lose weight. Women with PCOS often have
difficulty losing weight; roughly half of all women diagnosed with PCOS are
clinically obese (Hoegar, 2001). Maintaining a healthy lifestyle is crucial for

14
women diagnosed with polycystic ovary syndrome, as more than half of women
diagnosed can expect to develop prediabetes or type II diabetes mellitus prior to
the age of 40.
Psychological Implications of PCOS
As demonstrated by the wide variety of intrusive symptoms above, PCOS
can exert a strong influence on the lives of those with the syndrome. With such a
panoply of physiological symptoms, it is not surprising that negative
psychological consequences can co-occur with negative physiological symptoms.
PCOS and Depression
There has been a high prevalence of mood disorders found in women with
PCOS, particularly a high prevalence of depressive disorders (Rasgon et al, 2003).
Both clinical and biochemical symptom correlates have been found in women
diagnosed with PCOS, with depression being associated to greater insulin
resistance and higher BMI (Ragson et al, 2003). Thus, there appears to be an
association between depression and classic PCOS markers (Ragson et al, 2003).
Stress
Stress is a common and daily occurrence in modern society.
Physiologically, stress can be defined as a state in which homeostasis is
jeopardized by the action of external (environmental) and internal (physiological
and psychological states) stressors (Bozocvic, Racic, Ivkovic, 2013). In particular
to psychological state, stress is the experience of a perceived threat, resulting from
a series of physiological responses and pathways (Seaward, 2012).
Hypothalamic-Adrenal- Pituitary Axis
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One of the main systems that regulate the body’s response to stress is the
hypothalamic-pituitary-adrenal (HPA) axes. An integral part of the HPA axes, the
hypothalamus, is activated in response to a stressor, producing a “fight or flight”
response. First proposed by Seyle, this “fight or flight” response is the body’s
automatic response to stress, preparing the body to either face the stressor or
remove itself from the situation. This feedback response is first initiated by the
hypothalamus, which in turn activates the sympathetic nervous system, and finally
the adrenal-cortical system to eventually release cortisol.
Cortisol
The moments following an initial stressor are critical for the body to
physiologically prepare for an appropriate response to the stressor. The first
response of the body is by the hypothalamus, which is stimulated to related
corticotropin-releasing factor by the stressor. In response to this release of
corticotropin-releasing factor, the anterior gland is stimulated to release
adrenocorticotropic hormone (ACTH). Finally, the release of ACTH stimulates
the release of cortisol by the adrenal glands, which enters the bloodstream to
prepare the body to respond to the stressor. Cortisol, also known as
hydrocortisone, is a glucocorticoid (steroid hormone), released in response to the
HPA axes pathway, which begins after perception of a stressor. Cortisol’s primary
function is to maintain and increase blood sugar through gluconeogenesis,
suppress the immune system, and aid in metabolism. Simply, cortisol prepares the
body to respond to a stressor. Therefore, cortisol can be considered a biomarker,
or indicator, of HPA axis activity and the larger stress response. Cortisol has been
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demonstrated to be a biomarker of psychosocial stress (Selye et al., 1960;
Kirschbaum et al., 1995; Eck, 1996; Bozovic, Racic, & Ivkovic, 2013). Typical,
daily stressful events have been to induce a rapid increase in cortisol secretion
(Eck et al 1996), further demonstrating cortisol’s utility as a biomarker for
psychosocial stress.
Salivary Cortisol
In a laboratory setting, salivary cortisol is often collected as an indicator of
psychosocial stress. Through the framework described above, salivary cortisol can
be utilized as an objective biomarker for psychosocial stress. The present study
will analyze salivary cortisol samples for a measurement of psychosocial stress.
Chronic Stress
While the experience of stress is a daily occurrence, not all types of stress
are experienced equivalently. Distress, defined as an interpretation that an event
will have a negative and/or harmful effect on the interpreter (Ridner, 2004),
becomes increasingly problematic when the experience of stress is chronic.
Chronic, or prolonged stress, has been shown to have negative implications is
regards to psychological health and well-being; stressful events have been shown
to be contributing factors to depression (Hammen, 2005; Kendler et al. 1999) and
anxiety disorders (Brown et al. 1986).
Further, chronic stress has been demonstrated to be a contributing factor to
the development and experience of chronic disease, often accelerating disease
processes (Nestler et al., 2002). Implications of chronic stress have been
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documented in regards to many major diseases, including heart disease, immune
system and hormonal changes such as levels of cortisol (Kirschbaum et al, 1995).
While the effects of stress on physiological functions have been
investigated in regards to certain endocrine disorders such as diabetes, there has
been less focus on the effects of stress on other chronic, endocrine disorders. In
this paper, I will focus on the effects of stress on women with polycystic ovary
syndrome.
Polycystic Ovary Syndrome and Stress
The need for treatment directed to attenuate any psychological
implications of the syndrome has become increasingly important, particularly how
PCOS could affect the experience of stress in women diagnosed. As cited above,
women with PCOS may experience
While several researchers have focused on PCOS in a psychosocial
perspective, including research on depression, anxiety, and quality of life
(Cipkala-Gaffin et al, 2012); (Ferriday et al, 2007), fewer researchers have
examined the experiences of stress in women with PCOS, another psychosocial
experience that may be altered as a result of having PCOS. One striking example
was a study done by Benson et al., who found that women with PCOS had
disturbed stress responses, showing an enhanced hypothalamic-pituitary-adrenal
(HPA) axis and heart rate reactivity in response to a stress interview task (2008).
After the insertion of a catheter to measure serum cortisol, ACTH, and IL-6
levels, participants were asked to complete a public speaking task to elicit an
acute psychosocial stress response. It was supported that women with PCOS had
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significantly greater increases in HPA-axis mediators (ACTH and cortisol) than a
control population (Benson et al., 2008) This seminal work in regards to PCOS
and psychosocial stress demonstrates the need for a greater understanding of
stress reactivity in women with polycystic ovary syndrome.

Aims of the Present Study
Polycystic Ovary Syndrome and Experience of Stress
The present study aims to explore how polycystic ovary syndrome could
affect the health of women with the syndrome, and further, how these effects
could alter the experiences of stress in their lives. The study focused on the
following primary hypotheses.

Hypotheses
1. Women with polycystic ovary syndrome will report higher levels
of perceived stress than healthy age-matched controls

2. Women with polycystic ovary syndrome will report more somatic
complaints that are problematic to their daily lives.
3. Women with polycystic ovary syndrome will have a greater
baseline cortisol and greater cortisol reactivity over time to the
Social Competence Interview (SCI) compared to controls.
4. Somatic complaints will be related to psychosocial variables such
as depression, anxiety, perceived stress across all participants.
Methods
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Participants
Participants were recruited and screened via advertisements within
“SONA”, a research participation pool system at Syracuse University, with xx
being eligible to participate in the study. Also, participants were recruited and
screened via paper and electronic flyers around the Syracuse University campus
and surrounding neighborhoods. 78 women, 16 with polycystic ovary syndrome
and 62 without polycystic ovary syndrome, were included in data analyses.
Exclusion criteria included several lifestyle factors: currently smoking tobacco
products, heavy drinking (20 or more drinks per week), age and gender (only
women between the ages of 18-35 were eligible). Further, diagnoses of one or
more of the following health concerns would result in ineligibility: atopic
diseases, allergies requiring regular medications, airway disease (such as asthma),
autoimmune diseases, cardiovascular problems, gastrointestinal diseases, diseases
of the urinary tract, and any other hormonal disorders that were not polycystic
ovary syndrome.
The sample was 100 % female, as this was a study concerning women’s
health; all of the participants were female. The average age of the participants was
19.05 (SD=2.00) years old. 47% of the participants identified as White, 21%
identified as Asian, 15% identified as Black, and 13% were other races, more than
one race, or declined to state their race. The average BMI of the entire sample was
23.9 kg/m2, (SD=4.9) with the average waist-to-hip ratio (WHR) being .83 (SD=.
10).
Procedures
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Participants were invited to meet a member of the research team outside of
the CNY Medical Building near Syracuse University, who would guide them to
the Project Heart Laboratory. The participant was immediately asked if they had
any caffeine yet that day. If so, the participant was invited to reschedule their
appointment time, as the presence of caffeine could change the outcome of the
results. After ensuring the participant did not have any caffeine, the participant
was guided into a comfortable room, and then provided with a consent form to
read over on their own. A research assistant then asked the participant if they had
any questions on what they read. If there were no questions and the participant
felt comfortable with the procedures, the participant was invited to sign the
informed consent, which included information on the Social Competence
Interview and the methods to collect saliva samples at five repeated measures.
After signing the informed consent, general body measurements and
physiological data was collected, including: height (to the nearest quarter inch),
weight (in kg), and waist-to-hip ratio (WHR). Later, participant BMI was
calculated from the information collected during the study. Following this, the
participant was invited to complete the first series of questionnaires. These
questionnaires included basic demographic information, Perceived Stress Scale
(PSS) that measures perceived stress (Hewitt, Flett, & Mosher 1992), Symptom
Checklist (SCL) that collects somatic symptomatic data (Laan et al, 1999), the
Center for Epidemiologic Studies Depression (CES-D) Scale that measures selfreported depressive symptoms (Dam & Earlywine, 2011), a scale on body image,
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and a polycystic ovary syndrome health questionnaire that collected information
on the participant’s symptomatic experiences with PCOS.
After 30 minutes of calmly completing questionnaires, the first baseline
measurement of saliva (labeled “S0”) was taken. Prior to taking the baseline
measurement, participants were explained the proper procedure for saliva
collection utilizing salivette tubes. Participants were instructed to roll the salivette
around their mouth for 60 seconds, trying to reach all parts of their mouth.
Participants were instructed to refrain from touching the cotton salivette cylinder
with their hands, along with being instructed to refrain from biting the salivette.
After 10 minutes of quietly resting, a second baseline measurement (labeled “S1”)
was taken. At this point, the Social Competence Interview, or SCI, began. A
Research Assistant that had been trained on the SCI conducted the interview.
Three more saliva samples were taken throughout the study, one in the middle of
the Social Competence Interview, or SCI (S2), another at the end of the interview
(S3), and a last sample ten minutes following the interview (S4).
Following the SCI, participants were instructed to relax and complete a
second set of questionnaires, including two measures on self-reported quality of
life. The last saliva sample (S4) was taken 10 minutes after the interview was
complete. At this point, the participant continued to fill out and complete any
remaining questionnaires in the second questionnaire packet.
When the participants finished their final questionnaires, they were
thanked for their time and effort in completing the study, debriefed by one of the
Research Assistants, and guided out of the CNY Medical building. The entire
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protocol, including entering and exiting the laboratory space, lasted
approximately 90 minutes. Participants recruited through the SONA research
participation pool were awarded course credit as compensation. Participants
recruited through the campus and surrounding communities were awarded $15.00
as compensation for completing the study.
The Social Competence Interview
The SCI (Ewart at al, 2002) is an 8-12 minute interview designed to elicit
a short-term stress response. During the interview, participants are asked to
describe a recent, stressful situation related to a chronic stressor in their lives.
During the first portion of the interview, participants are asked to recall the
stressful situation they experienced in as much detail as possible. In the second
section of the interview, the participant is directed to describe a potential
solution(s) and coping mechanism(s) to the problem they were previously
describing. To develop potential solution(s) and coping mechanism(s), the
participant is then asked to pretend they are the director of a film. This film is
about character similar to themselves, who is experiencing the same chronic
stressor and specific stressful experience that the participant had previously
described. The participant can direct any ending for their character. Specifically,
they are asked to come up with an ideal, realistic ending to the film they
described, and are later asked to rate their confidence in achieving that particular
ideal ending. Participants were asked for their consent to be audio recorded
during their interview.
Measures
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Perceived Stress Scale. The Perceived Stress Scale (PSS) is a
psychological questionnaire used to measure an individual’s perception of stress
in their daily lives. Items in the questionnaire are designed to measure how
unpredictable, uncontrollable, and overloaded respondents find their lives (Cohen
et al, 1998).
Symptom Checklist. The Symptom Checklist-90-R (SCL-90-R) is a selfreport questionnaire, designed to evaluate a range of psychological and
physiological symptoms. In this study, we used an abbreviated measure, only
including a portion of the questionnaire items.
Center for Epidemiologic Studies- Depression Scale (CES-D). The CES-D
is a self-report questionnaire, designed to evaluate depression symptoms. In this
study, we used this measure to evaluate self-reported symptoms of depression in
the study sample.
All measures are presented in Appendix B.
Data Analysis Plan
All data analyses were conducted using IBM SPSS Statistics 21 statistical
software package (IBM, Chicago, IL, USA). Using descriptive statistics, I
analyzed the demographics of the study sample. I examined group differences
using a series of independent samples t-tests.
To test Hypothesis 1, whether women with polycystic ovary syndrome
reported higher levels of perceived stress than healthy age-matched controls, I
performed an independent samples t-test.
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To test Hypothesis 2, whether women with polycystic ovary syndrome
experienced more health concerns, i.e., more somatic complaints and more
depressive symptoms than healthy age-matched controls, I performed two more
independent samples t-tests.
To test Hypothesis 3, whether the Social Competence Interview (SCI)
elicited changes in cortisol and amylase over time in both women with polycystic
ovary syndrome and healthy age-matched controls, I performed a repeated
measures analysis of variance (ANOVA) comparing differences from Time 1
(baseline sample) to Time 3 (immediately after SCI).
To test Hypothesis 4, whether perceived somatic complaints were related
to psychosocial variables such as depression, anxiety, perceived stress, I
performed a series of Pearson’s correlations.
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Results

Means and standard deviations for all study variables of interest are
presented in Table 3 (Appendix A). Participants ranged in age from 18 to 29 and
had a mean age of 19.18 (SD= 1.79). The sample was comprised of 16 of women
with PCOS and 62 healthy controls. The two groups differed significantly in
BMI, t (78) = -3.69, p < .001. Women with PCOS had a mean BMI of 27.71
(SD=2.08) while the control group had a mean BMI of 22.99 (SD=. 374).

Hypothesis 1

The hypothesis that women with polycystic ovary syndrome would report
higher levels of perceived stress than healthy age-matched controls was tested
with an independent samples t-test. No significant group differences were found,
PCOS (M = 19.60, SD = 6.60) Control (M = 16.85, SD = 6.28), t (n-1) = -1.50 , p
> .05.

Hypothesis 2
The hypothesis that women with polycystic ovarian syndrome would
report more somatic complaints and depressive symptoms related to their daily
lives than healthy age-matched controls was tested with an independent samples ttest. Results revealed significant differences between the groups. Women with
PCOS (M = 31.46, SD = 21.48) reported significantly higher levels of perceived
somatic complaints than healthy controls (M = 21.16, SD = 11.59),
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t(71) = 2.44, p = .02. Women with PCOS (M=43.0, SD = 11.2) also reported
more symptoms of depression than healthy controls (M=36.9, SD=8.5), t(64) =
2.05, p=.05

Hypothesis 3
The hypothesis that women with polycystic ovary syndrome would have
greater physiological reactivity as measured by cortisol compared to controls was
tested with an independent samples t-test. Results revealed a significant difference
between the groups, but in the opposite direction than hypothesized. Women with
PCOS had a greater decline in cortisol (M= -1.67, SD= 2.93) than healthy
controls (M = -.31, SD =1.99), t(65) = 2.11, p= .04.

Further analysis via a repeated measures ANOVA showed that, for all
participants, the difference in change in cortisol level between the first baseline
time point (M = 9.89, SD = 4.94) and the third time point, immediately after the
SCI, (M = 8.39, SD = 4.31) was statistically significant, F(1,66) = 18.564, p <
.001. There was a significant decrement in cortisol from Time 1 to Time 3 across
all participants.
Means and standard deviations for cortisol samples for each time, by
group, is presented in Table 4 (Appendix A).

Hypothesis 4
The hypothesis that perceived somatic complaints were related to
psychosocial variables such as depression, anxiety, perceived stress was tested
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with Pearson Correlations were calculated.

There was a moderate, statistically

significant, positive correlation between somatic complaints and depression; r
(63) = .53, p<0.01.
There was a moderate, statistically significant, positive correlation
between somatic complaints and trait anxiety; r(40) = .49, p<0.01.
There was a moderate, statistically significant, positive correlation
between somatic complaints and reported perceived stress; r (63) = .55, p<0.01.
There was a moderate, statistically significant, positive correlation
between somatic complaints and BMI; r (70) = .33, p<0.01.

Discussion
The purpose of this study was to explore how polycystic ovary syndrome
affects the health of the women diagnosed, and how these effects could alter the
experiences of stress in their lives. We found that women with PCOS did not
report higher levels of perceived stress than healthy controls (Hypothesis 1).
Given that this was a college sample, it is possible that all participants
experienced similar levels of stress in their daily lives, independent of any
medical condition.

Although we did not find a difference in perceived stress, we did find that
women with PCOS reported more somatic complaints and depressive symptoms
than healthy controls. Given that PCOS is associated with many problematic
physical symptoms, i.e. hirsutism, acne, weight gain, and pelvic pain, it is
expected that women diagnosed with PCOS would have more somatic complaints
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compared to healthy controls. Along with physical symptoms, women with
polycystic ovary syndrome have been found to have high incidences of depressive
symptoms, ranging from 28 to 64 % of women diagnosed (Bazarganipour et al,
2013 ; Bhattacharya, 2010; Deeks, Gibson-Helm, Teede, 2010). My results
concurred with the previous literature, finding that women diagnosed with PCOS
reported more depressive symptoms than healthy controls. Similarly to somatic
complaints, the physical symptoms associated with PCOS may contribute to
increased depressive symptoms. In line with this, we found a moderate positive
correlation between somatic complaints and depressive symptoms across all
participants. As reported somatic complaints increased, so did the reported
depressive symptoms for all participants.

It is difficult to interpret the results of Hypothesis 3, that women with
PCOS would experience greater physiological reactivity to the SCI, because an
unexpected decline in salivary cortisol was observed for all participants
throughout the study, suggesting there was not an activation of the HPA axes due
to the SCI. Possibly, the most physiologically stressful part of the study was
meeting an unfamiliar Research Assistant to be brought to the laboratory. At the
end of the study, many participants reported feeling that the interview was
therapeutic, rather than stressful.

Across all participants, I found that there were moderate to strong
correlations between somatic complaints and reported depressive symptoms,
anxiety, and perceived stress. The results suggest that in my study sample,
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distressing physical symptoms may contribute to higher levels of psychiatric
symptoms.

Significance of Study
This study is one of the first to examine the implications of psychosocial
stressors in a specific population, women diagnosed with polycystic ovary
syndrome. Currently, this population is underserved in terms of psychological and
psychosocial research; this study serves to contribute to the deficit in knowledge
within the field.
This study is the first to examine indicators of physical health such as BMI
and somatic complaints, and indicators of mental health such as depressive
symptoms, anxiety, and perceived stress in college-age women diagnosed with
polycystic ovary syndrome. The study was also the first to examine changes in
cortisol in response to a psychosocial stressor, the Social Competence Interview,
in this population.
Strengths of this study include the fact that participants were screened for
existing medical conditions; participants with confounding medical conditions
(e.g., psychiatric illnesses such as Major Depressive Disorder, ADHD,
Generalized Anxiety Disorder, etc.) were not included in the study. Further, the
control population was large (N= 62) compared to the experimental group
(N=16).

Limitations
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Although this study had many areas of strength, there were still some
limitations. One key limitation is the sample size in women diagnosed with
polycystic ovary syndrome was small relative to the control population.
Considering this, it is difficult to draw conclusions that could generalize to a
broader population of women with polycystic ovary syndrome. Another key
limitation is that the laboratory stressor, the SCI, may not have induced an HPA
axes response, making it difficult to examine how this population responded to a
stressor. Lastly, my study mostly contained a population of relatively young,
college-educated women. Results may not be able to generalizable to a larger
population with more diverse backgrounds.

Future Directions
The findings from this study point to further research on the ties between
the experiences of stress and the relation to the physical and psychological health
in women diagnosed with polycystic ovary syndrome. This study supported that
somatic and psychological symptoms associated with PCOS are significantly
different than a healthy population. As a result, more research needs to be
conducted on how these symptoms could affect the daily lives of women affected.
Like for many who face disorders with difficult and often problematic
symptoms, the necessity of medical, psychological, and social support is
paramount. Thus, more research needs to be done on the potential benefits of
psychological support in women with polycystic ovary syndrome.
Finally, it has only been in recent years that PCOS has garnered attention
and credibility, both in the medical field and society. As a result, both women
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diagnosed with polycystic ovary syndrome and those hoping to raise awareness
for the syndrome may have difficulty finding the language to discuss the
syndrome. Therefore, an interesting line of research may include not only more
investigation on the psychological impacts of the disorder, but the best methods to
increase awareness and communication between health care practitioners, those
affected, and their larger communities.
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Appendix A

Table 3
Means, Standard Deviations, and Pearson Correlations for Selected Study
Variables
Mean (SD)
r
1.
Symptoms
Checklist*
2.
CES-D*

3.
Self-report
Trait Anxiety
4.
Percieved
Stress Scale
5.
BMI*

PCOS, 31.46 (21.48);
Control, 21.17 (11.60)
PCOS, 43.00(11.20);
Control, 36.90(8.54)
PCOS, xx(xx); Control,
43.97(11.29)
PCOS, 19.64 (7.58);
Control, 17.23(7.58)
PCOS, 27.71 (8.30);
Control, 22.99(2.99)

1.
1

2.

.740**

1

.052

-.062

.528**
.486**

1

.553**

.710**

.331**

3.

.827**

4.

1

.006

Note. ** indicates correlations significant at p < .01.
* indicates significant difference between means and standard deviations of
groups.
xx indicated data not included in analysis.
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Table 4
Means and Standard Deviations for Cortisol Samples by Group
Cortisol (nmol/L)
PCOS
Controls
Time 1
10.98 (6.44) 8.8 (4.4)
Time 2
10.31(7.04) 8.1 (3.2)
Time 3
9.20(6.50)
7.5 (3.4)
Time 4
8.64(5.99)
7.4 (3.1)
Time 5
7.34(4.84)
6.8 (3.5)
Note. PCOS, N=16, Control N=51
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The questions in this scale ask you about your feelings and thoughts during the last
month. In each case, please indicate with a check how often you felt or thought a
certain way.

1. In the last month, how
often have you been upset
because of something that
happened unexpectedly?
2. In the last month, how
often have you felt that you
were unable to control the
important things in your
life?
3. In the last month, how
often have you felt nervous
and "stressed"?
4. In the last month, how
often have you felt confident
about your ability to handle
your personal problems?
5. In the last month, how
often have you felt that
things were going your way?
6. In the last month, how
often have you found that
you could not cope with all
the things that you had to
do?
7. In the last month, how
often have you been able to
control irritations in your
life?
8. In the last month, how
often have you felt that you
were on top of things?

Never

Almost
never

Sometime
s

Fairly
often

Very often

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4
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9. In the last month, how
often have you been angered
because of things that were
outside of your control?
10. In the last month, how often
have you felt difficulties were
piling up so high that you could
not overcome them?

0

1

2

3

4

0

1

2

3

4
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CESD
Below is a list of the ways you might have felt or behaved. Please tell me how
often you have felt this way during the past week.
1 = Rarely or None of the Time (Less than 1 Day)
2 = Some or a Little of the Time (1-2 Days)
3 = Occasionally or a Moderate Amount of Time (3-4 Days)

1.

I was bothered by things that
usually don’t bother me.

1

2

3

4

2.

I did not feel like eating; my appetite
was poor.

1

2

3

4

3.

I felt that I could not shake off the
blues even with help from my family
or friends.

1

2

3

4

4.

I felt that I was just as good as other
people.

1

2

3

4

5.

I had trouble keeping my mind on
what I was doing.

1

2

3

4

6.

I felt depressed.

1

2

3

4

7.

I felt that everything I did was an
effort.

1

2

3

4

8.

I felt hopeful about the future.

1

2

3

4

9.

I thought my life had been a failure.

1

2

3

4

10.

I felt fearful.

1

2

3

4

11.

My sleep was restless.

1

2

3

4

12.

I was happy.

1

2

3

4

13.

I talked less than usual.

1

2

3

4

14.

I felt lonely.

1

2

3

4

15.

People were unfriendly.

1

2

3

4

16.

I enjoyed life.

1

2

3

4

17.

I had crying spells.

1

2

3

4

(5-7 Days)

Most or All of the Time

Amount of Time (3-4 Days)

Occasionally or a Moderate

(1-2 Days)

Some or a Little of the Time

(Less than 1 Day)

During the past week:

Rarely or None of the Time

4 = Most or All of the Time (5-7 Days)
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18.

I felt sad.

1

2

3

4

19.

I felt that people dislike me.

1

2

3

4

1

2

3

4

20. I could not get “going”.

SCL
Below is a list of symptoms that young adults sometimes have. Circle a number
telling how much you were bothered by each symptom during the past two
weeks.
In the last two weeks, how much were you bothered by each symptom?
Never

Almost
never

Sometime
s

Fairly
often

Very often

1. Headaches

0

1

2

3

4

2. Faintness or dizziness

0

1

2

3

4

3. Pain in your heart or
chest

0

1

2

3

4

4. Feeling low in energy or
slowed down

0

1

2

3

4

5. Pains in your lower back

0

1

2

3

4

6. Sore muscles

0

1

2

3

4

7. Trouble caution your
breath (when you're not
exercising)

0

1

2

3

4

8. Hot or cold spells
(suddenly feeling hot
or cold)

0

1

2

3

4

9. Numbness or tingling in
parts of your body

0

1

2

3

4

10. A lump in your throat

0

1

2

3

4

11. Weakness (feeling weak)
in parts of your body

0

1

2

3

4

12. Heavy feelings in your
arms or legs

0

1

2

3

4

13. Nausea or upset
stomach

0

1

2

3

4

14. Constipation

0

1

2

3

4

15. Loose (runny) bowel
movements or diarrhea

0

1

2

3

4

16. Pain in your stomach or
abdomen

0

1

2

3

4

17. Your heart beating too
fast

0

1

2

3

4

18. Difficulty swallowing

0

1

2

3

4

19. Losing your voice

0

1

2

3

4

20. Deafness

0

1

2

3

4

21. Double vision

0

1

2

3

4

22. Blurred vision

0

1

2

3

4

23. Blindness

0

1

2

3

4

24. Fainting or passing out

0

1

2

3

4

25. Memory loss or amnesia

0

1

2

3

4

26. Seizures or convulsions

0

1

2

3

4

27. Trouble walking

0

1

2

3

4

28. Paralysis or muscle
weakness

0

1

2

3

4

0

1

2

3

4

30. Vomiting

0

1

2

3

4

31. Feeling bloated or gassy

0

1

2

3

4

32. Food making you sick

0

1

2

3

4

33. Pain in your knees,
elbows or other joints

0

1

2

3

4

34. Pain in your arms or
legs

0

1

2

3

4

35. Pain when you urinate

0

1

2

3

4

29. Difficulty urinating

.

